Researchers have identified an enzyme linked to pregnancy-induced hypertension – also known as pre-eclampsia – a pregnancy complication characterized by high blood pressure and swelling due to fluid retention. The findings could be used to better screen for – and treat – this condition.
Pregnancy-induced hypertension, which occurs in approximately 10 percent of pregnancies, is a major cause of maternal and fetal deaths, yet the cause is unknown.
The study, led by researchers in Cleveland Clinic's Lerner Research Institute, examined mice for corin – an enzyme normally present in the heart – and determined that the deficiency of this enzyme in the uterus may be an underlying cause of the disease. The study was published today in Nature.
Pregnancy poses a major challenge for controlling blood pressure. As blood volume increases, maintaining normal blood pressure becomes more difficult. During pregnancy, the narrow, curly uterine arteries are enlarged to thin-walled vessels, an adaptive change important for maintaining normal maternal blood pressure and boosting blood flow to the fetus. However, in pregnant women with hypertension, the changes in uterine arteries become defective.
While this study was initially conducted on mice, the researchers extended their study to patients with pre-eclampsia. The researchers found that many pre-eclamptic patients had low levels of corin in their uterus, and corin gene mutations in pre-eclamptic patients were identified.
"Additional studies on corin or its related molecules may help to develop new methods to diagnose and treat pregnancy-induced hypertension," said Qingyu Wu, M.D., Ph.D., a researcher in the Department of Molecular Cardiology in Cleveland Clinic's Lerner Research Institute and the lead researcher on the study.
In this study, Dr. Wu and his staff collaborated with investigators at the Cyrus Tang Hematology Center of Soochow University in Suzhou, China, and Shanghai Jiaotong University in China, who conducted clinical studies.
About Cleveland ClinicCleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. About 2,800 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. Cleveland Clinic Health System includes a main campus near downtown Cleveland, eight community hospitals and 18 Family Health Centers in Northeast Ohio, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and opening in 2013, Cleveland Clinic Abu Dhabi. In 2010, there were 4 million visits throughout the Cleveland Clinic health system and 167,000 hospital admissions. Patients came for treatment from every state and from more than 100 countries. Visit us at www.clevelandclinic.org. Follow us at www.twitter.com/ClevelandClinic.
Dan Doron | EurekAlert!
New flexible, transparent, wearable biopatch, improves cellular observation, drug delivery
12.11.2018 | Purdue University
Exosomes 'swarm' to protect against bacteria inhaled through the nose
12.11.2018 | Massachusetts Eye and Ear Infirmary
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
Scientists developed specially coated nanometer-sized vehicles that can be actively moved through dense tissue like the vitreous of the eye. So far, the transport of nano-vehicles has only been demonstrated in model systems or biological fluids, but not in real tissue. The work was published in the journal Science Advances and constitutes one step further towards nanorobots becoming minimally-invasive tools for precisely delivering medicine to where it is needed.
Researchers of the “Micro, Nano and Molecular Systems” Lab at the Max Planck Institute for Intelligent Systems in Stuttgart, together with an international...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
12.11.2018 | Life Sciences
12.11.2018 | Materials Sciences
12.11.2018 | Physics and Astronomy